mProX™ Human STAT1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

STAT1, a transcription factor, has various applications in different fields of research. In the field of cancer, STAT1 has been studied in the context of intrahepatic cholangiocarcinoma (ICC) and renal cell carcinoma (RCC). In ICC, a DNA/RNA heteroduplex oligonucleotide targeting the chimeric site in FGFR2-AHCYL1 was found to inhibit ICC progression through posttranscriptional suppression of FGFR2 fusion. However, an EGFR-orchestrated bypass signaling axis partially offset the efficacy of the treatment. In RCC, the long non-coding RNA LINC00926 was found to promote RCC progression by regulating the miR-30a-5p/SOX4 axis and activating the IFNγ-JAK2-STAT1 pathway. LINC00926 may also be used as a biomarker to predict the response to immunotherapy in RCC patients. In the field of diabetes, STAT1 has been implicated in driving islet HLA-I hyperexpression in type 1 diabetes. The interferon/JAK-STAT axis, particularly STAT1, plays a key role in mediating the effects of interferons on HLA-I expression in beta-cells. JAK inhibitors have shown promise in diminishing HLA-I hyperexpression and may have implications for type 1 diabetes clinical management. In the field of spinal cord injury (SCI), protein kinase R (PKR) inhibition has been shown to protect against SCI by mitigating endoplasmic reticulum stress and pyroptosis. PKR interacts with STAT1, and STAT1 knockdown inhibits ER stress, pyroptosis, and inflammation in microglial cells. Finally, in the field of glioma, α-solanine, a bioactive compound, has been found to inhibit glioma proliferation and migration by regulating multiple targets and signaling pathways, including the positive regulation of MAP kinase activity and PI3K-Akt. These findings provide insights into the potential therapeutic applications of STAT1 in cancer, diabetes, spinal cord injury, and glioma.